Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Track all the latest updates and news of Concord Biotech IPO.
July 19, 2024 12:26:00 PM
Artiva Biotherapeutics has upsized its IPO to $167 million as the allogeneic natural killer (NK) cell therapy prepares to list on the Nasdaq this morning. | The biotech has knocked its share price ...
Published by : FierceBiotechJuly 17, 2024 8:15:00 AM
Actuate Therapeutics has set out plans for a modest $52 million IPO as the biotech seeks to fund a pair of trials for its glycogen synthase kinase-3 beta (GSK-3�) drug. The Texas- and Ireland-based ...
Published by : FierceBiotechJuly 19, 2024 11:39:00 AM
Cell therapy startup Artiva Biotherapeutics will go public on Friday morning in the 11th biotech IPO this year. Its Wall Street debut adds to the industry's modest rebuilding in 2024 following a ...
Published by : ENDPOINTS NEWSJuly 20, 2024 12:20:00 PM
A handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group.
Published by : Seeking AlphaJuly 19, 2024 8:33:00 PM
Shares of the clinical stage biotechnology company, backed by South Korea�s Green Cross Corp., traded as high as $16 each before retreating to their $12 IPO price on Friday in New York. Artiva sold ...
Published by : Bloomberg L.P.July 17, 2024 7:46:00 PM
More than a half-dozen hedge funds are gearing up for the next initial public offering of a fledgling biopharma company. The deal comes in the wake of two biopharma IPOs in June: One company was up ...
Published by : Institutional InvestorOctober 11, 2023 8:47:00 AM
(5) of SEBI (DP) regulation 2018, for quarter ended 30 June 2024, certificate issued by RTA & share transfer agent dated July 05, 2024 is attached, ...
Published by : money.rediffJuly 18, 2024 11:11:00 PM
The offering comes days after the publication of a paper showing what analysts said was early proof that �off-the-shelf� cell therapies can treat inflammatory diseases.
Published by : BioPharma DiveJuly 22, 2024 1:42:00 PM
When you invest in mutual funds, you have the option to choose from passive funds (which replicate existing indexes without the fund manager�s intervention); or go for active funds (where the fund ...
Published by : MintJuly 22, 2024 2:45:42 PM
The move comes at a time when the Centre is said to be already mulling ways to improve how investments towards Indian entities from Chinese companies pan out.
Published by : Live Mint on MSNThe IPO Shares of Concord Biotech Limited IPO are proposed to list on Friday, August 18, 2023 at BSE, NSE. The public issue of Concord Biotech IPO was opened on Aug 4, 2023 and closed for subscription on Aug 8, 2023. Concord Biotech IPO Listing Date and Information:
| Listing Date | Friday, August 18, 2023 |
| BSE Script Code | 543960 |
| NSE Symbol | CONCORDBIO |
| Listing In | |
| ISIN | INE338H01029 |
| Issue Price | ₹741 Per Equity Share |
| Face Value | ₹1 Per Equity Share |
The allotment status of Concord Biotech Limited IPO is now available online. The public issue of Concord Biotech IPO was open on Aug 4, 2023 and closed for subscription on Aug 8, 2023. The equity shares of the company to be list at BSE, NSE
.
Concord Biotech Limited is entering in the capital market with an IPO of 20,925,652 Equity Shares of Rs 1 aggregating up to Rs 1,551.00 Crore. The price for the issue has been set at Rs 705 - Rs 741 Per Equity Share.
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.
The issue opens on Aug 4, 2023 and closes for subscription on Aug 8, 2023. The equity shares of the company to be list at BSE, NSE.
The issue of Concord Biotech Limited opens on Aug 4, 2023 and closes for subscription on Aug 8, 2023. The equity shares of the company to be list at BSE, NSE. The price for the issue has been set at Rs 705 - Rs 741 Per Equity Share.
The Concord Biotech IPO is proposed to open on August 4, 2023. The IPO application ends on August 8, 2023.
Retail investors can apply in the retail or non-institutional investor category from August 4, 2023 to August 8, 2023. The Concord Biotech IPO can be applied online through Net Bank (ASBA method) or the stock broker (UPI method).
The Concord Biotech IPO will open for subscription on August 4, 2023. The public issue will close on August 8, 2023.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
